Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Abstract Text:

M Hassan-Alin,J Naesdal,C Nilsson-Pieschl,G ,T Andersson,

BACKGROUND: We investigated the potential interactions between esomeprazole and a non-selective nonsteroidal anti-inflammatory drug (NSAID; naproxen) or a cyclo-oxygenase (COX)-2-selective NSAID (rofecoxib) in healthy subjects. METHODS: Two studies of identical randomised, open, three-way crossover design were conducted. Subjects (n = 32 for both studies) were to receive 1 week's treatment with esomeprazole 40mg once daily (studies A and B), naproxen 250mg twice daily (study A), rofecoxib 12.5mg once daily (study B), and esomeprazole in combination with naproxen (study A) or rofecoxib (study B). Study periods were separated by a 2-week washout period. RESULTS: On day 7 of dosing, the ratios (and 95% CIs) for the area under the plasma concentration-time curve during the dosing interval (AUC(tau)) and observed maximum plasma concentration (C(max)) of esomeprazole and NSAID combination/NSAID alone were 0.98 (0.94, 1.01) and 1.00 (0.97, 1.04), respectively, for study A, and 1.15 (1.06, 1.24) and 1.14 (1.02, 1.28), respectively, for study B. The ratios (and 95% CIs) for AUC(tau) and C(max) of esomeprazole and NSAID combination/esomeprazole alone were 0.96 (0.89, 1.03) and 0.92 (0.85, 1.00), respectively, for study A, and 1.05 (0.96, 1.15) and 1.05 (0.94, 1.18), respectively, for study B. All treatments were well tolerated during the study period. CONCLUSION: Naproxen and rofecoxib do not interact with esomeprazole, and esomeprazole does not affect the pharmacokinetics of naproxen or rofecoxib. These findings indicate that esomeprazole can be used in combination with NSAIDs without the risk of a pharmacokinetic interaction.

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Publishing Authors By Initials

M Hassan-Alin,J Naesdal,C Nilsson-Pieschl,G ,T Andersson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical drug investigation

VOLUME: 25

Page Numbers: 731-40

Journal Abbreviation:

ISSN: 1173-2563

DAY: 29

MONTH: 05

YEAR: 2005

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9504817

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

AFFILIATION: AstraZeneca R&D Mölndal, Mölndal, Sweden.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Drug Investig

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects Related Publications

• Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
• Bone Ingrowth Through Porous Titanium Granulate Around a Femoral Stem: Histological assessment in a six-month canine hemiarthroplasty model.
• Cardiac reserve in the transplanted heart: effect of a graft polymorphism in the beta1-adrenoceptor.
• Case-referent study of cystic ovaries as a risk indicator for twin calvings in dairy cows.
• Cluster of Salmonella Enteritidis in Sweden 2005-2006 - suspected source: almonds.
• Duplication of FGF3, FGF4, FGF19 and ORAOV1 causes hair ridge and predisposition to dermoid sinus in Ridgeback dogs.
• Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.
• GRAT--genome-scale rapid alignment tool.
• GTP bound to chloroplast thylakoid membranes is required for light-induced, multienzyme degradation of the photosystem II D1 protein.
• Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in Malmö, Sweden 1976-1999.
• Inclusion of regional poroelastic material properties better predicts biomechanical behavior of lumbar discs subjected to dynamic loading.
• Intracellular pathogens go extreme: genome evolution in the Rickettsiales.
• Knowledge of emergency management of avulsed teeth among young physicians and dentists.
• LUTS treatment: future treatment options.
• Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.
• Loss-of-function mutation in carotenoid 15,15'-monooxygenase identified in a patient with hypercarotenemia and hypovitaminosis A.
• Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium.
• Muscarinic receptor antagonists for overactive bladder.
• Origin of mutations under selection: the adaptive mutation controversy.
• Outbreak of Salmonella Stanley in Sweden associated with alfalfa sprouts, July-August 2007.
• Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
• Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety.
• Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice.
• Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors.
• Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract.
• Settlement size and fertility in the Nordic countries.
• Structural analysis of altered large-subunit loop-6/carboxy-terminus interactions that influence catalytic efficiency and CO2/O2 specificity of ribulose-1,5-bisphosphate carboxylase/oxygenase.
• The importance of an active ongoing debate in science.
• Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.
• p16INK4a immunocytochemistry in liquid-based cervical cytology: is it feasible for clinical use?